Positioning Artificial Intelligence to Help Explain Unexpected Cancer Trial Outcomes
September 17th, 2026Phase 1 Data Support DAWN-303’s Evaluation of INCB161734 in Frontline KRAS G12D–Mutated PDACBrandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.Read more
Related Stories
AI News
Australia says OpenAI agent hacked government website
47 minutes ago
AI News
Are we back in big tech's 'move fast and break things' era?
47 minutes ago
AI News
Nick Clegg plays down fears ‘godlike’ AI could exterminate humanity
1 hour ago
AI News
For Pope Leo, the risk of an AI apocalypse is a major concern
1 hour ago
AI News
AI leaders Sam Altman and Dario Amodei acknowledge need for cooperation at UN
1 hour ago
AI News
Cyber startup Island hits $6.4 billion valuation in new round as AI attacks fuel spending wave
2 hours ago
AI News
UNGA81: Kenya Envoy calls for shared sovereignty as AI capabilities accelerate
2 hours ago
AI News
AI in the newsroom: It’s here, but needs guardrails
2 hours ago